Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Cancer

Categories

[Search within category]

FLT3 Mutations Associated with AC220 Drug Resistance in AML Patients

This invention provides methods for identifying acute myeloid leukemia (AML) patients that have an increased likelihood of a relapse following treatment with AC220.

Novel Radiotracers for Imaging Glucocorticoid Receptor in Treatment-resistant Cancer Patients

UCSF researchers have invented novel radiotracers that allow imaging of glucocorticoid receptor (GR) expression using positron emission tomography (PET) in patients with treatment-resistant solid cancer, including prostate, breast, ovarian and lung cancer.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Omnidirectional MRI Catheter Resonator for Interventional Procedures

This invention describes an orientation-independent device that can create bright and highly localized signal enhancement during magnetic resonance imaging.

A Mouse Model of Human Papillomavirus (HPV) infection for Drug Discovery

UCSF researchers have generated and validated a K14-HPV16 transgenic mouse model, in which transgene expression produces neoplastic progression that fully resembles the gynecological and other epithelial dysplastic lesions induced by high risk HPVs. This model offers an invaluable tool for studying HPV infection and developing new drugs for HPV treatment.

Selective Inhibition of Activated ErbB Tyrosine Kinases

This invention identifies a novel class of ErbB targeting small molecules.

Unconstrained Radiosurgery with Greatly Improved Dosage Fall Off

This invention describes a novel approach to radiosurgery that removes current constrains on stereotactic radiosurgery to reduce exposure of healthy brain tissue to radiation, thereby minimizing off-target brain damage.

A Companion Diagnostic for Lung Cancer Patients with Tyrosine Kinase Inhibitor (TKI) Resistance

This invention contains methods of measuring AXL and GAS6 expression and/or activity in lung cancer tumors with tyrosine kinase treatment resistance.

A Real-time Intraoperative Fluorescent Imaging Device for Guided Surgical Excision of Microscopic Residual Tumors

This novel real-time imaging device can provide precise and rapid pathological imaging information of the tumor area by utilizing fluorescent or luminescent markers within the body to ensure complete surgical resection.

Novel Software for Generating Attenuation Correction Maps with MRI for PET Reconstruction

This invention can accurately and rapidly map patient bone structure and classify all tissue types such as fatty soft tissue, water soft tissue, lung tissue, bone, and air within a single scan using novel MRI acquisition and reconstruction techniques.

Novel Compounds Targeting LRH-1for Treatment of Inflammatory Bowel Disease, Type II Diabetes, Triple Negative Breast Cancer & Pancreatic Cancer

This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.

Molecular Diagnosis And Classification Of Malignant Melanoma

These novel sets of biomarkers predict the five year survival rate of melanoma patients.

A Novel Therapeutic Target and Diagnostic/Prognostic Marker for Lung Adenocarcinoma

This invention identifies a novel non-coding RNA (ncRNA) transcript as a potential diagnostic and prognostic marker for lung adenocarcinoma. Furthermore, inhibitors of this novel ncRNA might hold therapeutic potential.

NOVEL GLIOMA-SPECIFIC VACCINE FOR PEDIATRIC AND YOUNG-ADULT PATIENTS

UCSF researchers have developed a vaccine against pediatric gliomas by targeting a novel epitope.  

Plasma Biomarkers for Monitoring Cancer Chemotherapy Efficacy

Highly sensitive protein biomarkers that can be used to monitor the extent of apoptosis in order to optimize chemotherapy regimen in cancer patients

TUMOR SELECTIVE MACROPINOCYTOSIS-DEPENDENT RAPIDLY INTERNALIZING ANTIBODIES

This invention establishes a novel method of therapeutic delivery to target tumor cells by macropinocytosis.

Novel Predictive Cancer Biomarker for PARP lnhibitors in Cancer Treatment

This novel biomarker predicts the treatment response of PARP inhibitors in cancer patients.

Methods And Reagents For Live Biopsy

This invention identifies a set of antibodies that allow direct imaging of immune cells in a tumor biospecimen.

Novel ELISA assay to detect SULF2 in patient samples

This ELISA technique detects Sulfatase2 (SULF2), an extracellular heparan sulfate-degrading enzyme that is overexpressed in many cancers. Furthermore, this technique can potentially serve as a diagnostic for cirrhosis.

A Novel Tumor Targeting Strategy for Cancer Chemotherapy

A novel small molecule tumor-activated prodrug technology that produces a therapeutic index multiplying effect, leading to reduced drug-associated toxicity and improved efficacy in cancer patients.

NOVEL DRUG DELIVERY DEVICE FOR PATIENTS AT RISK FOR BREAST CANCER

This novel device enables the localized, controlled delivery of chemopreventative agents to the breast tissue of patients at risk for developing breast cancer. 

NOVEL, POTENT ANTIANDROGEN ANALOG TO TREAT PROSTATE CANCER

This invention identifies a novel analog of the antiandrogen Casodex to effectively treat prostate cancer and hormone-based syndromes. Normal 0 false false false EN-US JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}

NOVEL SMALL MOLECULE COMPOUNDS FOR TARGETED CANCER THERAPEUTICS

A novel class of small molecules with a unique mechanism of action has been developed to inhibit MYC, a promising cancer target that has been proven undruggable, until now.

Anti-Human Sulf-2 monoclonal antibodies for research applications

This invention identifies novel mouse monoclonal antibodies that recognize both human and mouse Sulf-2, an enzyme that is overexpressed in many cancers.

Novel Serum miRNA Biomarkers for Prostate Cancer Diagnosis

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortality in adult American men, with an estimated 217,730 new cases diagnosed in the U.S. in 2010.  Screening for prostate-specific antigen (PSA) has led to earlier detection of prostate cancer.  However, elevated serum PSA can be present in other non-malignant conditions, such as benign prostatic hyperplasia and, therefore, PSA screening has a high false positives rate.  Active surveillance (AS) of prostate cancer is a current strategy that is used to reduce overtreatment by monitoring of low-risk patients with physical exams, PSA assessments and repeat biopsies, and offering treatment to those with signs of progression.  However, nomograms that utilize these predictors of disease progression demonstrate an accuracy of only 61-79% in the clinic.  Given the limitations of PSA and significant disease that can be used to categorize patients with localized prostate cancer and assist in treatment decision-making.  Several recent studies have shown that serum miRNA signatures have potential value as prognostic tools for prostate cancer.

  • Go to Page: